1. Inhibition of GTPase KRASG12D: a review of patent literature
- Author
-
Li, Yuhang, Yang, Le, Li, Xiaoran, and Zhang, Xiaojin
- Abstract
ABSTRACTIntroductionKRAS is a critical oncogenic protein intricately involved in tumor progression, and the difficulty in targeting KRAS has led it to be classified as an ‘undruggable target.’ Among the various KRAS mutations, KRASG12Dis highly prevalent and represents a promising therapeutic target, yet there are currently no approved inhibitors for it.Area coveredThis review summarizes numerous patents and literature featuring inhibitors or degraders of KRASG12Dthrough searching relevant information in PubMed, SciFinder and Web of Science databases from 2021 to February 2024, providing an overview of the research progress on inhibiting KRASG12Din terms of design strategies, chemical structures, biological activities, and clinical advancements.Expert opinionSince the approval of AMG510(Sotorasib), there has been an increasing focus on the inhibition of KRASG12D, leading to numerous reports of related inhibitors and degraders. Among them, MRTX1133, as the first KRASG12Dinhibitor to enter clinical trials, has demonstrated excellent tumor suppression in various KRASG12D-bearing human tumor xenograft models. It is important to note, however, that understanding the mechanisms of acquired resistance caused by KRAS inhibition and developing additional combination therapies is crucial. Moreover, seeking covalent inhibition of KRASG12Dalso holds significant potential.
- Published
- 2024
- Full Text
- View/download PDF